Evidence map›Paper›PMID 32319647›Full record

ReviewMolecular medicine reports2020

COVID‑19 in Northern Italy: An integrative overview of factors possibly influencing the sharp increase of the outbreak (Review).

Marina Goumenou, Dimosthenis Sarigiannis, Aristidis Tsatsakis, Ourania Anesti, Anca Oana Docea, Dimitrios Petrakis, Dimitris Tsoukalas, Ronald Kostoff, Valeri Rakitskii, Demetrios A Spandidos and 2 more

Abstract readReview
In one paragraph

Review in Molecular medicine reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Regional Differences in Mortality Rates During the COVID-19 Epidemic in Italy.Disaster medicine and public health preparedness · 2022
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. The Impact ofDiabetes, metabolic syndrome and obesity : targets and therapy · 2023
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marina Goumenou *Center of Toxicology Science and Research, Medical School, University of Crete, 71003 Heraklion, Greece.
Dimosthenis Sarigiannis *HERACLES Research Center on the Exposome and Health, Center for Interdisciplinary Research and Innovation, Aristotle University of Thessaloniki, 57001 Thessaloniki, Greece.
Aristidis Tsatsakis *Center of Toxicology Science and Research, Medical School, University of Crete, 71003 Heraklion, Greece.
Ourania AnestiCenter of Toxicology Science and Research, Medical School, University of Crete, 71003 Heraklion, Greece.
Anca Oana DoceaDepartment of Toxicology, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Dimitrios PetrakisCenter of Toxicology Science and Research, Medical School, University of Crete, 71003 Heraklion, Greece.
Dimitris TsoukalasMetabolomic Medicine, Health Clinics for Autoimmune and Chronic Diseases, 10674 Athens, Greece.
Ronald KostoffResearch Affiliate, School of Public Policy, Georgia Institute of Technology, Gainesville, VA 20155, USA.
Valeri RakitskiiFederal Scientific Center of Hygiene, F.F. Erisman, 141014 Moscow, Russia.
Demetrios A SpandidosLaboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Greece.
Michael AschnerI.M. Sechenov First Moscow State Medical University (Sechenov University), 119146 Moscow, Russia.
Daniela CalinaDepartment of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Italy is currently one of the countries seriously affected by the COVID‑19 pandemic. As per 10 April 2020, 147,577 people were found positive in a total of 906,864 tests performed and 18,849 people lost their lives. Among all cases, 70.2% of positive, and 79.4% of deaths occurred in the provinces of Northern Italy (Lombardi, Emilia Romagna, Veneto and Piemonte), where the outbreak first started. Originally, it was considered that the high number of positive cases and deaths in Italy resulted from COVID‑19 initially coming to Italy from China, its presumed country of origin. However, an analysis of the factors that played a role in the extent of this outbreak is needed. Evaluating which factors could be specific for a country and which might contribute the most is nevertheless complex, with accompanying high uncertainty. The purpose of this work is to discuss some of the possible contributing factors and their possible role in the relatively high infection and death rates in Northern Italy compared to other areas and countries.

Indexed as

COVID-19Disease OutbreaksHumansItalyPandemicsRisk FactorsSARS-CoV-2coronaviruscoVid-19italypandemic diseasespublic healthrisk factorsSarS-coV-2

Identifiers

PMID32319647
PMCPMC7248465

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.